ATM-deficient lung, prostate and pancreatic cancer cells are acutely sensitive to the combination of olaparib and the ATR inhibitor AZD6738
N. R. Jette, S. Radhamani, R. Ye, Y. Yu, G. Arthur, S. Goutam, T. Bizmar, M. Kumar, P. Bose, S. Yip, M. Kolinsky, S. P. Lees-MIller
This study shows that ATM-deficient cancer cells are more sensitive to the combination of olaparib and AZD6738, leading to cell death.
bioRxiv · Mar 13, 2020Cancer Biology